Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kremsner, P. G.
Right arrow Articles by Rocha, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kremsner, P. G.
Right arrow Articles by Rocha, R. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1989) 23, 275-281
© 1989 The British Society for Antimicrobial Chemotherapy

research-article

Clindamycin treatment of falciparum malaria in Brazil

Peter G. Kremsner, Gertraud M. Zotter, Hermann Feldmeier, Wolfgang Graninger, Richard L. Westerman and Roraima M. Rocha

Landesinstitut für Tropenmedizin Berlin, FRG: Universitätsklinik für Chemotherapie, University of Vienna Austria: Superintendencia de Campanhas de Saude Public Acre, Brazil

Received 29 July 1988; accepted 23 October 1988

Correspondence to: Dr Kremsner, Landesinstitut für Tropenmedizin Berlin, Königin-Elisabeth-Straße 321, D-1000 Berlin 19, Federal Republic of Germany

Oral treatment with clindamycin (5 mg/kg twice a day, for five consecutive days) was studied in patients with uncomplicated falciparum malaria in Acre, Brazil, an area with multiresistant Plasmodium falciparum.

Parasitaemia ranged between 12 and 79560/µl of blood admission. Thirty-five out of 44 patients admitted to the study could be followed up for 28 days. Only two patients showed parasitaemia six days after admission, and no asexual parasites were observed by day seven. Twenty-eight days after admission all patients were cured.

Of the nine patients withdrawn from the study, five were lost during follow up and four needed different treatment (quinine 15 mg/kg twice a day, for ten days) because clinical symptoms did not improve within 60 h after admission. These patients had experienced their first attack by P. falciparum.

In individual cases oral clindamycin can be used as an alternative treatment in semi-immune patients with uncomplicated falciparum malaria from an area where multiresistant parasites frequently occur. However, because of the slow response in all cases described here, and the risk of development of resistance if clindamycin is used alone it cannot be recommended as monotherapy in non-immune patients.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
B. Lell, R. Ruangweerayut, J. Wiesner, M. A. Missinou, A. Schindler, T. Baranek, M. Hintz, D. Hutchinson, H. Jomaa, and P. G. Kremsner
Fosmidomycin, a Novel Chemotherapeutic Agent for Malaria
Antimicrob. Agents Chemother., February 1, 2003; 47(2): 735 - 738.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Wiesner, D. Henschker, D. B. Hutchinson, E. Beck, and H. Jomaa
In Vitro and In Vivo Synergy of Fosmidomycin, a Novel Antimalarial Drug, with Clindamycin
Antimicrob. Agents Chemother., September 1, 2002; 46(9): 2889 - 2894.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
B. Lell and P. G. Kremsner
Clindamycin as an Antimalarial Drug: Review of Clinical Trials
Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2315 - 2320.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.